

Trag 3 (Taxol-resistant-associated protein 3). Rabbit Antigen Immunoaffinity Purified Polyclonal , Human

Taxol-resistant-associated protein 3

BACKGROUND

The expression of the cancer-testis antigen Taxol resistance-associated gene-3 (TRAG-3) is associated with acquired paclitaxel (Taxol) resistance, and is expressed in a variety of cancers - e.g., breast cancer, leukemia, and melanoma. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myelanoma lines 8226/Dox(40) and 8226/MDR (10)V. Weakly expressed in kidney. TRAG-3 is an attractive target for immunotherapy of cancer.

First identified as a novel cancer/testis antigen, TRAG-3, (Taxol Resistance Associated Gene-3) was initially discovered in a search for new genes involved in drug resistance. Early studies of TRAG-3 revealed a minimal to absent expression in normal tissues and a marked over-expression in many carcinoma cell lines including several melanoma lines. By RT-PCR evaluation of TRAG-3 two transcripts are seen in many carcinoma cell lines with products in the the 799 bp and a second alternatively spliced transcript.

ORDERING INFORMATION

CATALOG NUMBER
X1871P

SIZE
50 µg

FORM
Affinity Purified

HOST/CLONE
Rabbit

FORMULATION
Provided as ligand affinity purified antibody in phosphate buffered saline with 0.08% sodium azide

CONCENTRATION
Lot Specific

ISOTYPE
IgG

APPLICATIONS
Western Blot (others not tested)


IMMUNOGEN

Synthetic peptide derived from the human Trag-3 protein.

SPECIES REACTIVITY

Human

Legend: Western blot of endogenous Trag3 present in Jurkat cell lysate (15 ug/lane) using X1871P (0.5 ug/ml) and developed using anti-rabbit HRP (1:75k) and Pierce's Super Signal West Femto.



For research use only. Not for use in human diagnostics or therapeutics.

POSITIVE CONTROL/TISSUE EXPRESSION

Weakly expressed in kidney. Expressed in various tumor cell lines including carcinomas, myeloid and lymphoid malignancies, melanomas and prostate cancer. Overexpressed in taxol-resistant breast cancer line MDA 435(TR) and the doxorubicin-resistant multiple myeloma lines 8226/Dox(40) and

COMMENTS

Antibody can be used for Western blotting (0.5-2 µg/ml). Optimal concentration should be evaluated by serial dilutions.

SHIP CONDITIONS

Ship at ambient temperature, freeze upon arrival

STORAGE CUSTOMER

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

STABILITY

Products are stable for one year from purchase when stored properly

REFERENCES

- 1: Janjic B, et al. Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15;177(4):2717-27.
- 2: Ohta M, et al. Expression of the TRAG-3 gene in human esophageal cancer: the frequent synchronous expression of MAGE-3 gene. Oncol Rep. 2006 Jun;15(6):1529-32.
- 3:Aung PP, et al. Systematic search for gastric cancer-specific genes based on SAGE data: melanoma inhibitory activity and matrix metalloproteinase-10 are novel prognostic factors in patients with gastric cancer. Oncogene. 2006 Apr 20;25(17):2546-57.
- 4: Zhu B, et al. In vitro induction of immune response by dendritic cells pulsed with TRAG-3-derived cytotoxic T lymphocyte epitope] Zhonghua Zhong Liu Za Zhi. 2004 Dec;26(12):709-12. Chinese.
- 5: Meier A, et al. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol Immunother. 2005 Mar;54(3):219-28. Epub 2004 Oct 2.
- 6: Yao X, et al. Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet. 2004 May;151(1):1-13.
- 7: Wu YZ, et al. Expression of TRAG-3 in breast cancer. Int J Cancer. 2003 Oct 20;107(1):167-8.

LAST MODIFIED 8/30/2007

For research use only. Not for use in human diagnostics or therapeutics.